세계의 심근증 치료 시장 2019-2023

■ 영문 제목 : Global Cardiomyopathy Therapies Market 2019-2023

Technavio가 발행한 조사보고서이며, 코드는 IRTNTR30336 입니다.■ 상품코드 : IRTNTR30336
■ 조사/발행회사 : Technavio
■ 발행일 : 2018년 12월 3일
■ 페이지수 : 108
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 글로벌, 미주, 유럽, 아시아
■ 산업 분야 : 의료
■ 판매가격 / 옵션 (부가세별도)
Single User (1명 열람용)USD2,500 ⇒환산₩2,750,000견적의뢰/주문/질문
Five User (5명 열람용)USD3,000 ⇒환산₩3,300,000견적의뢰/주문/질문
Enterprise License (전사내 공유가능)USD4,000 ⇒환산₩4,400,000견적의뢰/구입/질문
가격옵션 설명
- 지불하실 금액은 상기 원화금액에 부가세(10%)를 더한 금액입니다.
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제이며, 세금계산서 발행 가능합니다.
본 조사보고서는 심근증 치료의 세계시장에 대해서 조사분석한 자료로서, 심근증 치료의 세계시장규모, 시장동향, 시장환경 분석, 세그멘트별 분석, 지역별 분석 (미주, 유럽, 아시아), 관련기업 정보등이 포함되어 있습니다.
■ 보고서 개요

About this marketAdvent of genomic medicine to push market growth during the forecast period. Cardiomyopathy is one of the major causes of heart failure. Genomic medicine is an emerging field in healthcare, it uses gene-related information of an individual. Technavio’s analysts have predicted that the cardiomyopathy therapies market will register a CAGR of almost 2% by 2023.
Market Overview
Initiative to increase awareness about disease
There has been an increase in initiatives to spread awareness about cardiomyopathy among people in the last few years.
High cost of treatment
Cardiomyopathy makes it difficult for the heart to pump blood to rest of the body. The condition can be treated by surgically implanting devices within the heart, these devices are quite expensive. This high cost associated with the treatment of cardiomyopathy may pose a challenge to the market.
For the detailed list of factors that will drive and challenge the growth of the cardiomyopathy therapies market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately concentrated and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the advent of genomic medicine and the initiative to increase awareness about disease, will provide considerable growth opportunities to cardiomyopathy therapies manufactures. AstraZeneca, Merck, Pfizer, and Sanofi are some of the major companies covered in this report.

■ 보고서 목차

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Dilated cardiomyopathy – Market size and forecast 2018-2023
• Hypertrophic cardiomyopathy – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Market trends
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Merck
• Pfizer
• Sanofi
PART 15: APPENDIX
• Research methodology
List of abbreviations

Exhibit 01: Years in consideration
Exhibit 02: Global CVD treatment market
Exhibit 03: Segments of global CVD treatment market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline drugs in late-stage clinical trials
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Threat of rivalry
Exhibit 14: Market condition – Five forces 2018
Exhibit 15: Type – Market share 2018-2023 (%)
Exhibit 16: Comparison by type
Exhibit 17: Dilated cardiomyopathy – Market size and forecast 2018-2023 ($ millions)
Exhibit 18: Dilated cardiomyopathy – Year-over-year growth 2019-2023 (%)
Exhibit 19: Hypertrophic cardiomyopathy – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Hypertrophic cardiomyopathy – Year-over-year growth 2019-2023 (%)
Exhibit 21: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Others – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by type
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 31: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Decision framework
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: AstraZeneca – Vendor overview
Exhibit 43: AstraZeneca – Business segments
Exhibit 44: AstraZeneca – Organizational developments
Exhibit 45: AstraZeneca – Geographic focus
Exhibit 46: AstraZeneca – Key offerings
Exhibit 47: Merck – Vendor overview
Exhibit 48: Merck – Business segments
Exhibit 49: Merck – Organizational developments
Exhibit 50: Merck – Segment focus
Exhibit 51: Merck – Key offerings
Exhibit 52: Pfizer – Vendor overview
Exhibit 53: Pfizer – Business segments
Exhibit 54: Pfizer – Organizational developments
Exhibit 55: Pfizer – Geographic focus
Exhibit 56: Pfizer – Segment focus
Exhibit 57: Pfizer – Key offerings
Exhibit 58: Sanofi – Vendor overview
Exhibit 59: Sanofi – Business segments
Exhibit 60: Sanofi – Organizational developments
Exhibit 61: Sanofi – Segment focus
Exhibit 62: Sanofi – Key offerings
Exhibit 63: Validation techniques employed for market sizing
Exhibit 64: List of abbreviations



■ 기재된 기업 리스트

AstraZeneca, Merck, Pfizer, Sanofi


■ 보고서의 키워드

심근증 치료


■ 조사 방법

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

※본 조사보고서 [세계의 심근증 치료 시장 2019-2023] (코드 : IRTNTR30336) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 심근증 치료 시장 2019-2023] 에 대해서 E메일 문의는 여기를 클릭하세요.